UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 16, 2002
Genetronics Biomedical Corporation
| Delaware | 0-29608 | 33-0969592 | ||
|
|
||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
| 11199 Sorrento Valley Road, San Diego California | 92121-1334 | |
|
|
||
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including area code (858) 597-6006
Not Applicable
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events.
On August 16, 2002, ICN Biomedicals, Inc. (“ICN”) informed Genetronics Biomedical Corporation (“Genetronics”) that it had decided not to complete the purchase of the BTX Instrument Division of Genetronics. ICN exercised this right pursuant to the terms of an Asset Purchase Agreement between ICN and Genetronics dated June 19, 2002. Exhibit 99.1 is the press release issued to announce ICN’s decision not to complete the purchase of the BTX Division.
Item 7. Financial Statements and Exhibits.
| Exhibit | ||
| No. | Description | |
| 99.1 | Press release issued August 16, 2002 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Genetronics Biomedical Corporation | ||
| | ||
| Date: August 19, 2002 | By: | /s/ Avtar Dhillon |
| Avtar Dhillon, President and Chief Executive Officer | ||
EXHIBIT INDEX
| Exhibit | ||
| No. | Description | |
| 99.1 | Press release issued August 16, 2002 |